



| | |
|--|---------------------------------------|
| Sponsor: Sanofi | |
| Product Code: GZ419828 | Product INN: AGALSIDASE BETA |
| Study Code: LPS15919 | EUDRACT Number: 2019-000065-20 |
| Title of the study: A randomized, open-label, active comparator, 2-arm, prospective study to assess the glycosphingolipid clearance and clinical effects of switching to agalsidase beta (Fabrazyme®) versus continuing on migalastat (Galafold®) in male patients with classic Fabry disease | |

Study Status: **No patient screened, no patient randomized, no patient exposed to the treatment at the time of the study premature stop.**

Reason of early termination: **The Sponsor terminated the study due to recruitment infeasibility in the context of the covid pandemy and without having been able to enroll any patient in the few months before**